Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citalopram add-on therapy for resistant hypertension
IRCT20260719070255N1Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of citalopram in resistant hypertension (RH) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Change in systolic blood pressure from baseline to 2 months, Change in diastolic blood pressure from baseline to 2 months and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
citalopram
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on IRCT20260719070255N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260719070255N1.